Clinical policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department

Annals of Emergency Medicine

Volumn 61, Issue 2, 2013, Pages 225-243

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; EVIDENCE BASED EMERGENCY MEDICINE; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; STROKE PATIENT;

EID: 84872518801     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2012.11.005     Document Type: Review

References (46)

1. D. Lloyd-Jones, R.J. Adams, T.M. Brown American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
2. D.L. Schriger, S.V. Cantrill, C.S. Greene The origins, benefits, harms and implications of emergency medicine clinical policies Ann Emerg Med 22 1993 597 602
3. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
4. M. Mitka Tensions remain over tPA for stroke JAMA 289 2003 1363 1364
5. P.D. Lyden, K.R. Lees, S.M. Davis Alteplase for acute stroke revisited: the first 10 years Lancet Neurol 5 2006 722 724
6. J.L. Saver Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke Arch Neurol 61 2004 1066 1070
7. The NINDS t-PA Stroke Study Group Generalized efficacy of t-PA for acute stroke Subgroup analysis of the NINDS t-PA stroke trial Stroke 28 1997 2119 2125
8. G.A. Donnan, S.M. Davis, B.R. Chambers Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group JAMA 276 1996 961 966
9. Multicentre Acute Stroke Trial-Italy (MAST-I) Group Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke Lancet 346 1995 1509 1514
10. The Multicenter Acute Stroke Trial-Europe Study Group Thrombolytic therapy with streptokinase in acute ischemic stroke N Engl J Med 335 1996 145 150
11. W. Hacke, M. Kaste, C. Fieschi Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke The European Cooperative Acute Stroke Study (ECASS) JAMA 274 1995 1017 1025
12. W. Hacke, M. Kaste, C. Fieschi Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators Lancet 352 1998 1245 1251
13. W.M. Clark, G.W. Albers, K.P. Madden Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study Stroke 31 2000 811 816
14. W.M. Clark, S. Wissman, G.W. Albers Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke Study Investigators Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset The ATLANTIS Study: a randomized controlled trial JAMA 282 1999 2019 2026
15. G.W. Albers, W.M. Clark, K.P. Madden ATLANTIS trial: results for patients treated within 3 hours of stroke onset Stroke 33 2002 493 496
16. T.J. Ingall, W.M. O'Fallon, K. Asplund Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial Stroke 35 2004 2418 2424
17. K.R. Lees, E. Bluhmki, R. von Kummer Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 375 2010 1695 1703
18. J.R. Hoffman, D.L. Schriger A graphic reanalysis of the NINDS trial Ann Emerg Med 54 2009 329 336
19. W. Hacke, M. Kaste, E. Bluhmki ECASS Investigators Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
20. G.J. Del Zoppo, J.L. Saver, E.C. Jauch American Heart Association Stroke Council Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association Stroke 40 2009 2945 2948
21. D.Z. Wang, J.A. Rose, D.S. Honings Treating acute stroke patients with intravenous tPA The OSF Stroke Network experience Stroke 31 2000 77 81
22. A.M. Lopez-Yunez, A. Bruno, L.S. Williams Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage Stroke 32 2001 12 16
23. I.L. Katzan, A.J. Furlan, L.E. Lloyd Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience JAMA 283 2000 1151 1158
24. D.M. Bravata, N. Kim, J. Concato Thrombolysis for acute stroke in routine clinical practice Arch Intern Med 162 2002 1994 2001
25. C.E. Szoeke, M.W. Parsons, K.S. Butcher Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital Med J Aust 178 2003 324 328
26. J.E. Bray, K. Coughlan, C. Bladin Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital Intern Med J 36 2006 483 488
27. G.W. Albers, V.E. Bates, W.M. Clark Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study JAMA 283 2000 1145 1150
28. M.D. Hill, A.M. Buchan Canadian Alteplace for Stroke Effectiveness Study (CASES) Investigators Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study CMAJ 172 2005 1307 1312
29. N. Wahlgren, N. Ahmed, A. Davalos SITS-MOST Investigators Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study Lancet 369 2007 275 282
30. N. Ahmed, N. Wahlgren, M. Grand SITS-MOST Investigators Implementation and outcome of thrombolysis with alteplase 3-4.5 hours after an acute stroke: an updated analysis from SITS-ISTR Lancet Neurol 9 2010 866 874
31. M.J. Alberts, G. Hademenos, R.E. Latchaw Recommendations for the establishment of primary stroke centers Brain Attack Coalition JAMA 283 2000 3102 3109
32. J.W. Norris, A. Buchan, R. Cote Canadian guidelines for intravenous thrombolytic treatment in acute stroke A consensus statement of the Canadian Stroke Consortium Can J Neurol Sci 25 1998 257 259
33. M. Fisher Developing and implementing future stroke therapies: the potential of telemedicine Ann Neurol 58 2005 666 671
34. M.P. LaMonte, M.N. Bahouth, P. Hu Telemedicine for acute stroke: triumphs and pitfalls Stroke 34 2003 725 728
35. S. Wang, H. Gross, S.B. Lee Remote evaluation of acute ischemic stroke in rural community hospitals in Georgia Stroke 35 2004 1763 1768
36. L.H. Schwamm, E.S. Rosenthal, A. Hirshberg Virtual TeleStroke support for the emergency department evaluation of acute stroke Acad Emerg Med 11 2004 1193 1197
37. H.J. Audebert, C. Kukla, B. Vatankhah Comparison of tissue plasminogen activator administration management between telestroke network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany Stroke 37 2006 1822 1827
38. B.C. Meyer, R. Raman, T. Hemmen Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomized, blinded, prospective study Lancet Neurol 7 2008 787 795
39. L.H. Schwamm, H.J. Audebert, P. Amarenco American Heart Association Stroke Council, Council on Epidemiology and Prevention, Interdisciplinary Council on Peripheral Vascular Disease, Council on Cardiovascular Radiology and Intervention Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association Stroke 40 2009 2635 2660
40. H.P. Adams Jr, G. del Zoppo, M.J. Alberts Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke 38 2007 1655 1711
41. G.W. Albers, P. Amarenco, J.D. Easton Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 483S 512S
42. P.N. Sylaja, R. Cote, A.M. Buchan Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study J Neurol Neurosurg Psychiatry 77 2006 826 829
43. S.T. Engelter, M. Reichhart, L. Sekoranja Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis Neurology 65 2005 1795 1798
44. D. Tanne, M.J. Gorman, V.E. Bates Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience Stroke 31 2000 370 375
45. The NINDS t-PA Stroke Study Group Generalized efficacy of t-PA for acute stroke Subgroup analysis of the NINDS t-PA Stroke Trial Stroke 28 1997 2119 2125
46. Sandercock P, Wardlaw JM, Lindley RI, et al, for the IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h or acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomized controlled trial. Lancet. doi:10.1016/S0140-6736(12)60768-5.